-
Poised to be one of the latest generation ventricular assist devices (VADs) to win FDA approval is the HeartMate II from Thoratec (Pleasanton, California). The company featured the device during the Scientific Sessions of the Heart Failure Society of America (St. Paul, Minnesota) by making available at its exhibit area two real-life case studies: two people implanted with the device.
-
Cardiovascular disease remains the No. 1 cause of death in Europe, making the market for products used in diagnosing, monitoring and treating heart disease and stroke one of the largest segments of the medical device market in the region.
-
As a result of safety issues with DES recently reinforced by the COURAGE study, and others, indicating that PCI/stenting may offer no greater length of life than medical therapy utilization has declined substantially, particularly in the U.S. where usage has slumped from 87% of procedures in 2005 to the current rate of 64%, according to cardiologists at the ESC congress.
-
The fifth annual Vascular Interventional Advances (VIVA) meeting took place in Las Vegas in late September, with that gathering seeking to integrate all four specialties involved in the care of patients with vascular disease: vascular surgery, interventional cardiology, vascular medicine and interventional radiology.
-
The Agency for Healthcare Research and Quality (AHRQ; Washington) and the FDA last month said that they will collaborate on a study to examine the potential for increased cardiovascular problems related to the use of prescription drugs to treat attention deficit hyperactivity disorder (ADHD).
-
German researchers have found that heart disease of the left main coronary artery is often an inherited condition that clusters in families.
-
Advanced Cell Technology (ACT; Alameda, California) completed its previously disclosed acquisition of the outstanding capital stock of Mytogen (Charlestown, Massachusetts).
-
Your patent counsel comes to you and tells you that the best way to fight off a patent infringement claim is to argue that your product offers a larger risk of adverse events than the other company's product, so it couldn't be infringing.
Say what?
-
Cardica (Redwood, City, California) and Cook Medical (Bloomington, Indiana) reported expansion of an agreement regarding the development of vascular closure devices first disclosed in June.
-
In-stent restenosis is a major issue when it comes to percutaneous coronary intervention of coronary vessels, often requiring patients to undergo repeat procedures, or more invasive surgery. And this is an even more vexing problem when it comes to occluded vessels of the leg.
